Reeling after the Phase IIb failure of its “breakthrough” gene therapy for heart failure, Celladon is slashing its budget and payroll, vowing to find a way forward that preserves value for its investors.

…read more

Source: Celladon halves its workforce to conserve cash after gene therapy meltdown